APT Medical Inc (688617) Fair Value & Analysis
Healthcare · CN · Market cap 29.7B CNY
Fair value as of: Aug 7, 2026
From 26 valuation models · updated 3 days ago
Share price +10.4% over the past month.
A strong business, but screening 46% overvalued on our models.
What matters now
- A high-quality business (quality 76/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (¥87.07 to ¥270.61). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 7, 2026.
How to read this chart
60‑month range ¥67.58 – ¥330.49 · fair‑value band ¥87.07 – ¥270.61 · the ¥208.50 price screens above the ¥113.16 fair value. Dashed = 300-day average. As of Aug 7, 2026.
Analysis
APT Medical Inc (688617) currently trades at ¥208.50, while our model-based Fair Value estimate is ¥113.16, implying the stock looks roughly 45.7% overvalued today. The Quality Score stands at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, APT Medical Inc generated revenue of 2.7B CNY at a net margin of 31.8%. Revenue grew 24.8% year over year. It earns a return on equity of 29.7%. The balance sheet holds a net cash position of 1.2B CNY. Fundamentals as of Aug 7, 2026
Our scenario range runs from ¥87.07 (bear case) to ¥270.61 (bull case); at ¥208.50, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -46%, 688617 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥258.91) versus Asset-Based (¥14.62). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 77 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
APT Medical Inc. engages in the research and development, production, and sale of cardiovascular interventional medical devices in China.
Full company description
APT Medical Inc. engages in the research and development, production, and sale of cardiovascular interventional medical devices in China. It offers electrophysiology products, such as navigation systems, navigated catheters, mapping catheters, ablation catheters, transseptal needles and sheaths, and steerable sheaths; and interventional cardiology and peripheral products, including access, diagnostic products, therapeutic products, and accessories. The company also manufactures and supplies EP and vascular intervention medical devices. In addition, it provides OEM and ODM services comprising project design and development, customization, and volume OEM; and customized products consisting of catheters, guidewires, and delivery systems, as well as nitinol products in cardiology, peripheral, neurology, and urology. APT Medical Inc. was founded in 2002 and is headquartered in Shenzhen, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
APT Medical Inc reported revenue of ¥2.6B in FY2025 versus ¥829M in FY2021, a compound +32.9%/yr. Reported net income was ¥821M in FY2025, compounding +40.9%/yr from FY2021.
688617 screens 46% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare APT Medical Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is APT Medical Inc (688617) overvalued or undervalued?
What is the fair value of 688617?
What is the quality score of 688617?
What is the revenue of APT Medical Inc (688617)?
What is the net profit margin of 688617?
Does APT Medical Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track APT Medical Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.